Consumer Products
Personal Care
Biopharmaceutical

Veru

$1.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.99%) Today
-$0.02 (-1.16%) After Hours

Why Robinhood?

You can buy or sell Veru and other stocks, options, ETFs, and crypto commission-free!

About

Veru Inc. Common Stock, also called Veru, is a urology and oncology biopharmaceutical company, which engages in the development, manufacture and marketing of consumer health care products. Read More It operates through the Commercial; and Research and Development segments. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1971 and is headquartered in Miami, FL.

Employees
171
Headquarters
Miami, Florida
Founded
1971
Market Cap
109.89M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
127.46K
High Today
$1.83
Low Today
$1.70
Open Price
$1.78
Volume
126.74K
52 Week High
$2.37
52 Week Low
$1.18

Collections

Consumer Products
Personal Care
Biopharmaceutical
Advertising and Marketing
Healthcare
Research And Development
Retail
Pharmaceutical

News

Seeking AlphaMay 16

Veru Inc. CEO Mitchell Steiner on Q1 2019 Results - Earnings Call Transcript

Veru Inc. (NASDAQ:VERU) Q1 2019 Earnings Conference Call May 15, 2019 8:00 AM ET Company Participants Mitchell Steiner - Chairman, Chief Executive Officer and President Michele Greco - Chief Financial Officer and Chief Administrative Officer Phil Greenberg - Executive Vice President, Legal Conference Call Participants Kumar Raja - Brookline Capital Leland Gershell - Oppenheimer Yi Chen - H.C. Wainwright Peter McMullin - Tiger Management Operator Good morning, ladies and gentlemen and welcome to V...

51
Yahoo FinanceMay 8

Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th

MIAMI, May 08, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals, today announced that on Wednesday, May 15, 2019, the Company will report financial results for its fiscal 2019 second quarter ended March 31, 2019, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. Eastern Time to revie...

86
Yahoo FinanceMay 1

Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Wall Street expects a year-over-year increase in earnings on higher revenues when Veru (VERU) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

77

Earnings

-$0.15
-$0.11
-$0.07
-$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.06 per share
Actual
-$0.06 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.